Fig. 3From: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD studyChanges from baseline to week 48 in renal laboratory parameters based on demographic characteristics. D/C/F/TAF darunavir/cobicistat/emtricitabine/tenofovir alafenamide, SE standard error, RBP retinol binding protein. *The total number of patients in each treatment arm for each subgroup is reported at the bottom of the figureBack to article page